Cargando…

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma

Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: de Souza, Ana Amélia, Altemani, Albina, de Araujo, Ney Soares, Texeira, Lucas Novaes, de Araújo, Vera Cavalcanti, Soares, Andresa Borges
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764050/
https://www.ncbi.nlm.nih.gov/pubmed/31598607
http://dx.doi.org/10.1177/2632010X19873384
_version_ 1783454295455170560
author de Souza, Ana Amélia
Altemani, Albina
de Araujo, Ney Soares
Texeira, Lucas Novaes
de Araújo, Vera Cavalcanti
Soares, Andresa Borges
author_facet de Souza, Ana Amélia
Altemani, Albina
de Araujo, Ney Soares
Texeira, Lucas Novaes
de Araújo, Vera Cavalcanti
Soares, Andresa Borges
author_sort de Souza, Ana Amélia
collection PubMed
description Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA.
format Online
Article
Text
id pubmed-6764050
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67640502019-10-09 Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma de Souza, Ana Amélia Altemani, Albina de Araujo, Ney Soares Texeira, Lucas Novaes de Araújo, Vera Cavalcanti Soares, Andresa Borges Clin Pathol Brief Report Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA. SAGE Publications 2019-09-26 /pmc/articles/PMC6764050/ /pubmed/31598607 http://dx.doi.org/10.1177/2632010X19873384 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Brief Report
de Souza, Ana Amélia
Altemani, Albina
de Araujo, Ney Soares
Texeira, Lucas Novaes
de Araújo, Vera Cavalcanti
Soares, Andresa Borges
Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
title Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
title_full Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
title_fullStr Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
title_full_unstemmed Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
title_short Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
title_sort estrogen receptor, progesterone receptor, and her-2 expression in recurrent pleomorphic adenoma
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764050/
https://www.ncbi.nlm.nih.gov/pubmed/31598607
http://dx.doi.org/10.1177/2632010X19873384
work_keys_str_mv AT desouzaanaamelia estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma
AT altemanialbina estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma
AT dearaujoneysoares estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma
AT texeiralucasnovaes estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma
AT dearaujoveracavalcanti estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma
AT soaresandresaborges estrogenreceptorprogesteronereceptorandher2expressioninrecurrentpleomorphicadenoma